A double-blind, placebo-controlled, crossover trial to investigate the PPR of approximately 5 subjects with a known stable PPR on EEG, using 2 doses of NPT 2042 compared to placebo.

开始日期2024-08-21

申办/合作机构

NeuroPro Therapeutics, Inc.初创企业

NCT05503511 / Completed临床1期

A Single-center, Randomized, Placebo Controlled, Double-blind, Ascending Single-dose and Repeated-dose Trial to Determine the Safety and Pharmacokinetic Profile of NPT 2042 Soft-Gelatin Capsules Administered Orally to Healthy Adult Subjects

Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.

开始日期2022-10-20

申办/合作机构

NeuroPro Therapeutics, Inc.初创企业

100 项与 Bumetanide analog(NeuroPro Therapeutics, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Bumetanide analog(NeuroPro Therapeutics, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Bumetanide analog(NeuroPro Therapeutics, Inc.) 相关的专利（医药）

登录后查看更多信息

项与 Bumetanide analog(NeuroPro Therapeutics, Inc.) 相关的文献（医药）

2024-03-01·Acta Crystallographica Section C Structural Chemistry

Crystal structure and Hirshfeld surface analysis of a salt of antineoplastic kinase inhibitor vandetanib

Article

作者: Liang, Minyi ; Yang, Haiwu ; Tian, Fang

A salt of vandetanib, namely, 4-({4-[(4-bromo-2-fluorophenyl)amino]-6-methoxyquinazolin-7-yl}methoxy)-1-methylpiperazin-1-ium 2-(butylamino)-4-phenoxy-6-sulfamoylbenzoate acetonitrile monosolvate, C22H25BrFN4O2+·C17H19N2O5S−·C2H3N, composed of kinase inhibitor vandetanib and sulfamyl diuretic bumetanide in a 1:1 molar ratio, is reported. There is proton transfer between the piperidine ring of vandetanib and the carboxyl group of bumetanide to form the salt. In the vandetanib cation, the arene and pyrimidine rings are not coplanar, their planes subtending a dihedral angle of 60.47 (14)°. The roles of the intermolecular interactions in the crystal packing were clarified using Hirshfeld surface analysis, and two-dimensional fingerprint plots indicate that the most important contributions to the crystal packing are from H...H (40.5%), O...H/H...C (20.7%), C...H/ H...C (18.8%) and N...C/C...N (9.0%) contacts.

100 项与 Bumetanide analog(NeuroPro Therapeutics, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
反射性癫痫	临床1期	美国	NeuroPro Therapeutics, Inc.初创企业	2024-08-21
阿尔茨海默症	临床1期	美国	NeuroPro Therapeutics, Inc.初创企业	2022-10-20
耐药性癫痫	临床1期	美国	NeuroPro Therapeutics, Inc.初创企业	2022-10-20